AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04801433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boleda Supramolecular Active Zinc Conditioner
Description: Boleda Supramolecular Active Zinc Conditioner (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
Study NCT04801433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capotetriol scalp solution
Description: Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
Study NCT04801433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supramolecular Hydrogel
Description: Supramolecular Hydrogel (Shanghai Ruizhi Pharmaceutical Technology Co., Ltd.): 30ml/bottle. Once a day for 4 weeks, apply topically to the scalp psoriasis area, gently massage for 15 minutes then rinse off with warm water.
Study NCT01766739 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GL-ONC1
Description: Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
Study NCT04588948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept
Description: Two arms (non-vitrectomized, and vitrectomized) are included in the study to evaluate the effect of vitrectomy on the intraocular and systemic pharmacokinetics of intravitreal aflibercept injection
Study NCT01174303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
Study NCT01174303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
Study NCT00438698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index diet
Description: Diet to emphasize carbohydrate foods low in glycemic index
Study NCT00438698 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Cereal Fibre Diets
Description: Diet to emphasize whole wheat carbohydrate cgoices
Study NCT04522908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib Oral Tablet
Description: Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
Study NCT03718585 — intervention group
Intervention type: OTHER
Intervention: whole exome sequencing analysis
Description: Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
Study NCT03839940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given as mouthwash
Study NCT03839940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as mouthwash
Study NCT03839940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study NCT03839940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire
Description: Ancillary studies
Study NCT03839940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03839940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03839940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Standard of care
Study NCT03839940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus
Description: Standard of care
Study NCT03269994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefoxitin
Description: Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
Study NCT03269994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Description: Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
Study NCT03337958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilatory re-education
Description: The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
Study NCT00827437 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parent Interview
Description: To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
Study NCT03760185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: All subjects will apply brimonidine tartrate to one eye (right eye) only for the duration of study participation.
Study NCT02064985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)
Description: To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
Study NCT04228835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescence Cholangiography
Description: Administration of ICG for fluorescence cholangiography
Study NCT02837848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coactivation Strengthening
Description: Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
Study NCT02837848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Strengthening
Description: Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
Study NCT01648101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine 900mg/day
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
Study NCT01648101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine 600mg/day
Description: Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
Study NCT01648101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
Study NCT01943305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis vaccine
Description: IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
Study NCT03149354 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assay of TSH, FT3 and FT4 by immuno-radiometric method
Description: Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
Study NCT03551392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medx Console System
Description: This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
Study NCT03551392 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Medx Console System
Description: This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
Study NCT03551392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vielight 810 intranasal stand alone unit
Description: Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
Study NCT03551392 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Vielight 810 intranasal stand alone unit
Description: Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week.
Study NCT01943305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever vaccine
Description: STAMARIL, 1 dose (0.5 ml)
Study NCT00307294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
Study NCT00307294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
Study NCT01155232 — intervention group
Intervention type: DRUG
Intervention: Teriparatide
Description: Forteo (teriparatide)pen daily for 24 months
Study NCT03779139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrahepatic islets and islets in the omental pouch
Description: Patients with islet harvest of >5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
Study NCT02839070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep/Wake Schedule
Description: Timing of sleep and wake
Study NCT03779139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrahepatic islets alone
Description: This is the standard of care procedure. Patients with islet harvest of >5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.
Study NCT03779139 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Volunteers
Description: These individuals will undergo metabolic testing as well as islet cell function testing.
Study NCT00275990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rheolytic thrombectomy with direct stenting
Study NCT04122976 — intervention group
Intervention type: DRUG
Intervention: Darolutamide(Nubeqa, BAY1841788)
Description: The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
Study NCT04186650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COL7A1-SIN retroviral vector engineered autologous tissue-engineered skin
Description: Graft of SIN RV-mediated COL7A1 gene-modified autologous skin equivalent
Study NCT02115282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and archived tissue samples
Study NCT02115282 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and archived tissue samples
Study NCT02115282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02115282 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02115282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO
Study NCT02115282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT02115282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Given PO
Study NCT02115282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Given PO
Study NCT02115282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin
Description: Given PO
Study NCT02115282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT02115282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC
Study NCT02115282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02115282 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02115282 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02115282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02115282 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02780583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kineret
Description: anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
Study NCT02780583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injection administered every 6 hours along with intravenous methylprednisolone
Study NCT01218958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 190 mg
Description: Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
Study NCT01218958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: IM injection once every 4 weeks for a total of 6 administrations.
Study NCT01218958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Medisorb naltrexone 190 mg
Description: IM injection once every 4 weeks for a total of 6 administrations.
Study NCT01218958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Medisorb naltrexone 380 mg
Description: IM injection once every 4 weeks for a total of 6 administrations.
Study NCT02185430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
Study NCT02185430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion
Description: dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
Study NCT02125851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xanthan Gum
Description: esophageal mucosal contact time vs sucralose slurry
Study NCT02125851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: esophageal mucosal contact time of honey vs sucralose slurry
Study NCT03070860 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan 18-FDG and 18-NAF
Description: Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG).
Study NCT03126058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enhanced recovery after surgery
Description: Patients will undergo enhanced recovery after surgery programs.
Study NCT00348699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFP464
Description: Given IV
Study NCT00348699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00348699 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02453165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRANSVAGINAL SUTURE
Description: The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
Study NCT02453165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC SUTURE
Description: The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
Study NCT03236259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brainport high dose
Description: berry extract, high dose. Daily ingestion of capsule
Study NCT03236259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Brainport low dose
Description: Berry extract, low dose. Daily ingestion of capsule
Study NCT03236259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin. Daily ingestion of capsule
Study NCT01647243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative strength training
Description: Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
Study NCT01829633 — intervention group
Intervention type: PROCEDURE
Intervention: Physiotherapy
Description: Shoulder physiotherapy with exercises
Study NCT05534659 — intervention group
Intervention type: DEVICE
Intervention: Programmable valve
Description: Programmable valve used in the study included Medtronic Strata, B-Braun ProGav, Codman Certas.
Study NCT05534659 — intervention group
Intervention type: DEVICE
Intervention: Non-programmable valve
Description: Non-programmable valve used in the study was Medtronic CSF-flow control valve.
Study NCT00275990 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct stenting
Study NCT02192931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Study NCT02192931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Creatine monohydrate
Study NCT04829903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Dulaglutide injections
Study NCT04829903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide injections
Study NCT06094569 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices
Study NCT00118963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Tablets of 500 mg; 1000 mg two times daily.
Study NCT00118963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Tablets of 500 mg; 1000 mg two times daily.
Study NCT00118963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin BIAsp30 (Novolog 70/30)
Description: Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
Study NCT00118963 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Repaglinide
Description: Tablets of 1 mg; Dosage: 2 mg three times daily.
Study NCT00118963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Tablets of 1 mg; Dosage: 2 mg three times daily.
Study NCT00118963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Metformin
Description: Tablets corresponding to 500 mg; two tablets two times daily.